Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine
Research Study Number | 9213 |
Principal Investigator | K. Scott Baker |
Phase | II |
Other eligibility criteria may apply.
Research Study Number | 9213 |
Contact | Seattle Cancer Care Alliance Intake Office |
Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Leukemia, Acute Myeloid (AML); Anemia, Aplastic; Fanconi Anemia; Hematologic Malignancies; Leukemia; Pediatric Cancers, Miscellaneous; Myelodysplastic Syndromes (MDS); Leukemia, Myeloid; Neoplasms; Anemia; Preleukemia; Bone Marrow Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.